Pharmaceutical CRO Market To Reach $83.31 Billion By 2033

Pharmaceutical CRO Market Growth & Trends

The global pharmaceutical CRO market size is expected to reach USD 83.31 billion by 2033, registering a CAGR of 8.04% from 2026 to 2033, according to a new report by Grand View Research, Inc. Pharmaceutical CROs provide outsourcing services to various pharmaceutical companies on a contract basis. Increasing outsourcing among pharmaceutical companies, growing investments in the R&D of new drugs, expansions in the pharmaceutical industry, and CRO support in reducing operational and capital expenses are some of the major factors anticipated to propel market growth in the forecast period.

Besides, increasing demand for CRO is driven by rising requirements for improved drug development, product maintenance, and related services, which is expected to drive market growth in the coming years. In addition, the substantial presence of key market players and ongoing clinical trials globally are expected to drive market growth. For instance, according to the U.S. National Library of Medicine, about 83,230 clinical trial studies are currently active and recruiting globally, which is anticipated to contribute to market growth. Likewise, increasing drug development activities, strategic initiatives such as innovation & acquisitions, the growing presence of pharmaceutical companies, and a surge in demand for pharmaceutical CRO innovative services are key factors propelling the market growth.

Furthermore, growing technological innovations pertaining to developing novel pharmaceutical drugs and rising research and development for biologics are anticipated to influence the market positively. Currently, pharmaceutical companies are increasingly bolstering their capacities in CRO's newer, highly specific expertise and technologies for the innovation of various small & large molecules. In addition, most pharmaceutical CROs have an emerging demand for small molecule drug candidates' development as CRO supports early discovery and preclinical drug development studies. For instance, in March 2023, Crown Bioscience & JSR Life Sciences Company mentioned it's a new site in Singapore, which will support the company in expanding its capacity for biotech & pharma companies. The site will help companies that engage in preclinical & translational oncology drug discovery and development.

 Request a free sample copy or view report summary: Pharmaceutical CRO Market Report

Pharmaceutical CRO Market Report Highlights

• Based on type, the clinical segment held the largest market share of 75.34% in 2025. The segment is driven by the increasing volume of drug development programs.

• Based on molecule, the small molecule segment held the largest share in 2025. Small-molecule therapies continue to drive drug development and outsourcing across discovery and clinical stages.

• Based on service, clinical monitoring segment dominated the market with a share in 2025, which is attributed to the increase in the adoption of monitoring of regulatory requirements and clinical trial management, which includes protocol development to data analysis, making it a suitable option for a wide range of clinical trials.

• In terms of therapeutic areas, the oncology segment held the largest market share in 2025. The segment is driven by the growing incidence of cancer, the rising aging population, and the robust demand for pharmaceuticals, contributing to its prominence in this field.

• Asia Pacific dominated the market globally with a revenue share of 40.45% in 2025. The region's high share is due to an increased number of actively functioning CROs, especially in China and Japan, among others.

Pharmaceutical CRO Market Segmentation

Grand View Research has segmented the global pharmaceutical CRO market based on product, application, end use and region:

Pharmaceutical CRO Type Outlook (Revenue, USD Billion, 2021 - 2033)

• Drug Discovery

  • Target Validation

  • Lead Identification

  • Lead Optimization

• Pre-Clinical

• Clinical

  • Phase I Trial Services

  • Phase II Trial Services

  • Phase III Trial Services

  • Phase IV Trial Services

Pharmaceutical CRO Molecule Type Outlook (Revenue, USD Billion, 2021 - 2033)

• Small Molecules

• Large Molecules

Pharmaceutical CRO Service Outlook (Revenue, USD Billion, 2021 - 2033)

• Project Management/Clinical Supply Management

• Data Management

• Regulatory/Medical Affairs

• Medical Writing

• Clinical Monitoring

• Quality Management/ Assurance

• Biostatistics

• Investigator Payments

• Laboratory

• Patient And Site Recruitment

• Technology

• Others

Pharmaceutical CRO Therapeutic Area Outlook (Revenue, USD Billion, 2021 - 2033)

• Oncology

• CNS Disorders

• Infectious Diseases

• Immunological Disorders

• Cardiovascular Disease

• Respiratory Diseases

• Diabetes

• Ophthalmology

• Pain Management

• Other

Pharmaceutical CRO Regional Outlook (Revenue, USD Million, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • UAE

  • Saudi Arabia

  • Kuwait

  • Qatar

  • Oman

List Of Key Players Pharmaceutical CRO Market

• Parexel International (MA) Corporation.

• ICON plc

• Laboratory Corporation of America Holdings

• Thermo Fisher Scientific Inc.

• Medpace

• IQVIA

• CTI Clinical Trial & Consulting

• WuXi AppTec

• Veeda Clinical Research